期刊文献+

分化型甲状腺癌前哨淋巴结的临床病理研究 被引量:2

Clinicopathological study of sentinel lymph node in patients with differentiated thyroid carcinoma
下载PDF
导出
摘要 目的 探讨检测分化型甲状腺癌前哨淋巴结(SLN)在预测颈部中央区淋巴结(CCLN)转移方面的价值。方法分析2013年1月~2015年12月首都医科大学宣武医院普外科253例分化型甲状腺癌患者,术中注射纳米炭后找到最先染色的SLN送冰冻病理,将其与CCLN术后石蜡病理进行对比,计算其阳性率。结果 253例患者均在术中成功找到SLN,平均5枚/例,其中假阴性率为21.1%,阳性预测值为81.8%,阴性预测值为78.7%。SLN活检数4~5个的诊断价值最大。结论 前哨淋巴结活检对于分化型甲状腺癌中央区淋巴结清扫有重要的指导意义,精准操作可以进一步提高其诊断价值。 Objective To investigate the value of sentinel lymph node (SLN) detection in predicting the metastasis of central cervical lymph nodes (CCLN)in differentiated thyroid carcinoma. Methods 253 patients with differentiated thy- roid carcinoma in Department of General Surgery, Xuanwu Hospital, Capital Medical University from January 2013 to December 2015 were analyzed. During the operation, carbon nanoparticles were injected and then to detect SLN which stained firstly by frozen pathology. Compared this results with the routine histopathology results of CCLNs and calculat- ed the positive rate. Results The detection rate of SLN was 100% and the average number of SLN was 5. The false negative rate, positive and negative predicted value of SLN to CCLN metastasis were 21.1%, 81.8%, 78.7%, respec- tively. When SLNs number reached 4-5, the diagnostic value was the highest. Conclusion There is an important pre- dicted value of SLN biopsy in CCLN excision for the patients suffered from differentiated thyroid carcinoma. It will be improved by precision operation.
出处 《中国医药导报》 CAS 2016年第27期35-38,共4页 China Medical Herald
基金 北京市卫生系统高层次卫生技术人才培养计划项目(2011-2-28)
关键词 分化型甲状腺癌 前哨淋巴结活检 中央区淋巴结 纳米炭 Differentiated thyroid carcinoma Sentinel lymph node biopsy Central lymph node Carbon nanoparticles
  • 相关文献

参考文献30

  • 1Chen W,Zheng R,Baade PD,et al. Cancer statistics in Chi- na,2015 [J]. CA Cancer J Clin, 2016,66(2) : 115-132.
  • 2Haugen BR,Alexander EK,Bible KC,et al. 2015 Ameri- can Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer:The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer [J]. Thyroid, 2015,26( 1 ) : 1-133.
  • 3Kowalski LP, Bagietto R, Lara JR, et al. Prognostic signifi- cance of the distribution of neck node metastasis from oral carcinoma [J]. Head Neck,2000,22(3) :207-214.
  • 4Mazzaferri EL. What is the optimal initial treatment of low- risk papillary thyroid cancer(and why is it eontroversial)[J]. Oncology (Williston Park), 2009,23 (7) : 579-588.
  • 5Shen WT,Ogawa L,Ruan D,et al. Central neck lymph node dissection for papillary thyroid cancer: the reliability of sur- geon judgment in predicting which patients will benefit [J]. Surgery,2010,148(2) :398-403.
  • 6Zuniga S, SanabriaA. Prophylactic central neck dissectionin stage NO papillary thyroid carcinoma [J]. Arch Oto- laryngol Head Neck Surg, 2009, 135 (11 ) : 1087-1091.
  • 7Hughes DT,Doherty GM. Central neck dissection for papil- lary thyroid cancer [J]. Cancer Control, 2011,18 (2) : 83-88.
  • 8De Carvalho AY,Chulam TC,Kowalski LP. Long-term results of observation vs prophylactic selective level VI neck dissec- tion for pap!llary thyroid carcinoma at a cancer center [J]. JAMA Otolaryngol Head Neck Surg,2015,141 (7) : 599-606.
  • 9Monacelli M,Lucchini R, Polistena A, et al. Total thyroidec- tomy and central lymph node dissection. Experience of a referral centre for endocrine surgery [J]. G Chir,2014,35(5- 6):117-121.
  • 10Kwan WY, Chow TL, Choi CY,et al. Complication rates of central compartment dissection in papillary thyroid can- cer [J]. ANZ J Surg,2015,85(4):274-278.

二级参考文献43

  • 1Krag DN, Meijer SJ, Weaver DL, et al. Minimal access surgery for staging of malignant melanoma[J]. Arch Surg, 1995,130(6):659 -660.
  • 2Borgstein PJ, Pijpers R, Comans EF, et al. Sentinel lymphoid node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection[J]. J Am Coll Surg , 1998, 186(3) :275 - 283.
  • 3Kelemen PR, Van Herle AJ, Giuliano AE. Sentinel lymphadenectomy in thyroid malignant neoplasms[J]. Arch Surg, 1998,133(3):288-292.
  • 4Carcangiu ML, Zampi G, Pupi A, et al. Papillary carcinoma of the thyroid[J]. Cancer, 1985, 55(4) :805 - 828.
  • 5Demeure MJ, Clark OH. Surgery in the treatment of thyroid cancer[J].Endocrinol Metab Clin North Am, 1990,19(3) :663 - 683.
  • 6Rbert PZ 3rd, Daniel WT, Gregory JR, et al. Intraoperative radiolymphescintigraphy for detection of occult nodal metastasis in patients with head and neck squamous cell carcinoma[J]. Otolaryngol Head Neck Surg, 2000, 122(5) :662- 666.
  • 7Pitman KT, Johnson JT, Edington H, et al. Lymphatic mapping with isosulfan blue dye in squamous cell carcinoma of the head and neck [J]. Arch Otolaryngol Head Neck Surg, 1998, 124(7):790-793.
  • 8Cooper DS,Doherty GM,Haugen BR. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer[J].{H}THYROID,2009,(11):1167-1214.
  • 9Yanir Y,Doweck I. Regional metastases in well-differentiated thyroid carcinoma:pattem of spread[J].{H}LARYNGOSCOPE,2008,(03):433-436.
  • 10Wang LY,Versnick MA,Gill AG. Level Ⅶ is an Important Component of Central Neck Dissection for Papillary Thyroid Cancer[J].{H}ANNALS OF SURGICAL ONCOLOGY,2013.

共引文献30

同被引文献22

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部